F2G Tops Up Funds For Launch Of New Class Of Antifungal
UK Firm To Go It Alone With US Commercialization
Having banked a $100m upfront fee from licensing partner Shionogi a couple of months ago, F2G has now unveiled a $70m financing to advance its late-stage novel oral antifungal, olorofim.
